= Emerging. More than 5 years before clinical availability. (9.82%)
= Expected to be clinically available in 1 to 4 years. (12.95%)
= Clinically available now. (22.77%)
MSACL 2018 EU : Smith

MSACL 2018 EU Abstract

Topic: Tissue Imaging

Podium Presentation in the Ether on Thursday at 9:20 (Chair: Raf Van de Plas)

MALDI-MSI in the Search for Proteomic Indicators of Response to Therapy in Membranous Nephropathy

Andrew Smith (Presenter)
University of Milano-Bicocca

Presenter Bio(s): I am currently a post-doctoral researcher at the University of Milano-Bicocca, with my principal line of research focusing on the MALDI-MS imaging of glomerular diseases.

I initially obtained my undergraduate degree from Sheffield Hallam University, reading Forensic and Analytical Science. Following which, my PhD programme was then completed at Milano-Bicocca, under the umbrella of a Marie Curie ITN.

Authors: Andrew Smith (1), Vincenzo L'Imperio (2), Elena Ajello (3), Fabio Pagni (2) and Fulvio Magni (1)
(1) Department of Medicine and Surgery, Clinical Proteomics and Metabolomics Unit, University of Milano-Bicocca, Vedano al Lambro, Italy (2) Department of Medicine and Surgery, Pathology, University of Milano-Bicocca, San Gerardo Hospital, Italy (3) Department of Medicine and Surgery, Nephrology Unit, University of Milano-Bicocca, Monza, Italy


Here we demonstrate how high spatial resolution MALDI-MSI can assist in the search for proteins able to predict response to treatment in Membranous Nephropathy patients. We present three proteins, macrophage migration inhibitory factor (MIF), Sonic Hedgehog (SHH) and α-smooth muscle actin (α-SMA), whose signal intensity and spatial localisation differed between patients who responded favourably or unvaourably to therapeutic treatment (Ponticelli Regimen). If verified in a larger sample cohort, such findings may have direct clinical relevance and could provide support in the prognostic assessment of MN patients.

Financial Disclosure

GrantsyesThe research leading to these results has received funding from MIUR: FIRB 2007 (RBRN07BMCT_11), FAR
Board Memberno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above: